ING Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ING Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-376,800	Closed	-$49.7M	–	588
2025 Q1	$49.7M	Buy	376,800 +364,300	+2,914%	+$45.4M	0.34%	56
2024 Q4	$1.04M	Buy	+12,500	New	+$1.03M	0.01%	497

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

ING Group's ITCI Position: Q2 2025 in Review

ING Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 376,800 shares — an estimated $49.7M sold.

ING Group first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $49.7M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

ING Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
ING Group sold 376,800 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $49.7M.
ING Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
ING Group's Intra-Cellular Therapies Inc. position peaked at $49.7M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on ING Group's 13F filing for Q2 2025, filed 6 Aug 2025.